

Special Issue

Global Analysis of Tracking the Evolution of SARS-CoV-2 Variants

Message from the Guest Editor

SARS-CoV-2, a positive-sense α -coronavirus, is the etiological agent of COVID-19. Although it possesses an error-prone viral RNA-dependent RNA polymerase with limited 3'-5' exoribonuclease activity, it can cause progeny viruses with new mutations, affecting its infectivity, transmissibility, and virulence. Moreover, recently, a sharp decline in PCR testing due to high cost and reliance on antigen testing kits could lead to the potential underreporting of new emerging variants. Therefore, the continuous monitoring and tracking of new variants on a globe scale, as well as the characterization of mutations, is crucial because of their effect on adaptive immunity, neutralizing antibody response, and impact on vaccine efficacy. The detailed maps of mutations highlighting their prospective role in therapeutics and vaccine development can better prepare us for future waves of continuously evolving SARS-CoV-2. With this aim, we invite original research and review articles which address the tracking and genomic surveillance of emerging variants, their virulence, transmissibility, mathematical modeling, and therapeutic aspects of COVID-19.

Guest Editor

Dr. Muhammad Atif Zahoor

Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/134954

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).